Based on our immuno-fluorescence data in Figure 4, caspase 3 was being cleaved (activated) after drug combination treatment, and we next investigated the molecular mechanisms by which [ruxolitinib + MMF] treatment was killing tumor cells. Here, CASP3 is linked to neoplasm.